On June 16, XtalPi Holdings fell 5.18% in regular trading, trading at HKD 6.59/share, with turnover of HKD 260 million. The stock continues its downtrend despite multiple recent positive announcements failing to reverse market sentiment.

On the news front, the company previously announced a strategic AI drug discovery partnership worth over USD 400 million targeting a GPCR oral drug candidate, alongside a USD 100 million share buyback program effective from June 10. However, market reaction has remained persistently cold. The partnership initially drove shares up over 4% at open on June 9, only to see rapid intraday reversal and continued selling pressure in subsequent sessions.

Despite revenue surging 201.2% year-over-year to RMB 803 million and achieving its first annual profit with an adjusted net income of RMB 258 million, the stock's dynamic price-to-earnings ratio remains elevated at approximately 212 times. Additionally, Hong Kong Stock Connect holdings are approaching the 50% purchase ceiling, while short-selling ratios remain elevated, creating structural capital flow constraints that have blunted the impact of positive catalysts. The broader Life Sciences Tools and Services sector also traded lower, with peers including Wuxi AppTec down 1.68%, Wuxi Biologics down 3.23%, GenScript Biotech down 4.07%, Wuxi XDC down 4.14%, and InSilico down 4.98%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)